Olanzapine plus fluoxetine treatment alters mitochondrial respiratory chain activity in the rat brain

Acta Neuropsychiatrica

Volumn 23, Issue 6, 2011, Pages 282-291

  Agostinho, Fabiano R ^a   Réus, Gislaine Z ^a   Stringari, Roberto B ^a   Ribeiro, Karine F ^a   Ferreira, Gabriela K ^a   Jeremias, Isabela C ^a   Scaini, Giselli ^a   Rezin, Gislaine T ^a   Streck, Emílio L ^a   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

bipolar depression; bipolar disorder; fluoxetine; mitochondrial respiratory chain; olanzapine

Indexed keywords

CYTOCHROME C OXIDASE; FLUOXETINE; OLANZAPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENERGY METABOLISM; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; MITOCHONDRIAL RESPIRATION; MOOD DISORDER; NONHUMAN; PREFRONTAL CORTEX; RAT; RESPIRATORY CHAIN;

EID: 82455189653     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2011.00569.x     Document Type: Article

References (67)

1. Nelson G, Hall GB, Forchuk C., Current and preferred housing of psychiatric consumers/survivors. Can J Commun Ment Health 2003; 22: 5-19. (Pubitemid 39243510)
2. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S., Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004; 61: 300-308. (Pubitemid 38295832)
3. Belmaker RH., Bipolar disorder. N Engl J Med 2004; 351: 476-486.
4. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ., Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004; 84: 386-392. (Pubitemid 38624764)
5. Kupfer DJ., The increasing medical burden in bipolar disorder. JAMA 2005; 293: 2528-2530. (Pubitemid 40705735)
6. Boekema EJ, Braun HP., Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Biol Chem 2007; 282: 1-4. (Pubitemid 47076588)
7. Fattal O, Budur K, Vaughan AJ, Franco K., Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006; 47: 1-7. (Pubitemid 43017115)
8. Prabakaran S, Swatton JE, Ryan MM, et al., Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-687.
9. Calabrese V, Scapagnini G, Giuffrida-Stella AM, Bates TE, Clark JB., Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 2001; 26: 739-764. (Pubitemid 32756837)
10. Armstrong JS., The role of the mitochondrial permeability transition in cell death. Mitochondrion 2006; 6: 225-234. (Pubitemid 44567384)
11. Schapira AH., Mitochondrial disease. Lancet 2006; 368: 70-82. (Pubitemid 43947206)
12. Gur RE, Resnick SM, Alavi A, Carrof S, Kushner M, Reivch M., Regional brain function in schizophrenia II: repeated evaluation with positron emission tomography. Arch Gen Psychiatry 1987; 44: 126-129. (Pubitemid 17006451)
13. Castanier C, Arnoult D., Mitochondrial dynamics apoptosis. Med Sci 2010; 26: 830-835.
14. Hung CH, Ho YS, Chang RC., Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease. Ageing Res Rev 2010; 9: 447-456.
15. Horn D, Barrientos A., Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life 2008; 60: 421-429.
16. Madrigal JLM, Olivenza R, Moro MA, et al., Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology 2001; 24: 420-429. (Pubitemid 32157558)
17. Shelton RC., The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination. Ther Clin Risk Manag 2006; 2: 187-192. (Pubitemid 43950055)
18. Tohen M, Vieta E, Calabrese J., Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2004; 60: 1079-1088.
19. Shelton RC, Tollefson GD, Tohen M, et al., A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134. (Pubitemid 32047260)
20. Rezin GT, Cardoso MR, Gonçalves CL, et al., Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int 2008; 53: 395-400.
21. Pittenger C, Duman RS., Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88-109. (Pubitemid 350191319)
22. Strakowski SM, Delbello MP, Adler CM., The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 2005; 10: 105-116. (Pubitemid 40139591)
23. Agostinho FR, Scaini G, Ferreira GK, et al., Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res Bull 2009; 80: 337-340.
24. Agostinho FR, Réus GZ, Stringari RB, et al., Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain. Neurosci Lett 2011; 487: 278-281.
25. Lowry OH, Rosebough NG, Farr AL, Randall RJ., Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
26. Cassina A, Radi R., Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys 1996; 328: 309-316. (Pubitemid 26160113)
27. Fischer JC, Ruitenbeek W, Berden JA, et al., Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin Chim Acta 1995; 153: 23-26.
28. Rustin P, Chretien D, Bourgeron T, et al., Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228: 35-51. (Pubitemid 24231224)
29. Marco R, Pestana A, Sebastian J, Sols A., Oxaloacetate metabolic crossroads in liver. Enzyme compartmentation and regulation of gluconeogenesis. Mol Cell Biochem. 1974; 3: 53-70.
30. Ben-Shachar D, Karry R., Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One 2008; 3: 3676.
31. Quiroz JA, Gray AN, Kato T, Manji HK., Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 2551-2565.
32. Iwamoto K, Bundo M, Kato T., Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005; 14: 241-253.
33. Kato T., Mitochondrial dysfunction in bipolar disorder: from 31P-magnetic resonance spectroscopic findings to their molecular mechanisms. Int Rev Neurobiol 2005; 63: 21-40. (Pubitemid 43588574)
34. Andreazza AC, Shao L, Wang JF, Young LT., Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67: 360-368.
35. Corrêa C, Amboni G, Assis LC, et al., Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 887-891. (Pubitemid 46660301)
36. Wang FJ, Shao L, Sun X, Young LT., Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neuron. J Neurochem 2004; 88: 1477-1484. (Pubitemid 38366924)
37. Dror E, Klein R, Karry A, et al., State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry 2002; 7: 995-1001.
38. Prince JA, Blennow K, Gottfries CG, Karlsson I, Oreland L., Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Europsychopharmacology 1999; 21: 372-379. (Pubitemid 29333075)
39. Streck EL, Rezin GT, Barbosa LM, Assis LC, Grandi E, Quevedo J., Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 127-133.
40. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr., Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993; 33: 512-517. (Pubitemid 23143036)
41. Modica-Napolitano JS, Lagace CJ, Brennan WA, Aprille JR., Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch Pharm Res 2003; 26: 951-559.
42. Maurer I, Moller HJ., Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 1997; 174: 255-259. (Pubitemid 27404200)
43. Ji B, La Y, Gao L, et al., A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J Proteome Res 2009; 8: 3633-3641.
44. Wu Y, Wu S, Lee W, Wei Y., Mitochondrial respiratory dysfunction-elicited oxidative stress and posttranslational protein modification in mitochondrial diseases. Ann N Y Acad Sci 2010; 1201: 147-156.
45. Paoszaj T, Robaszkiewicz A, Witas H., Oxidative damage of mitochondrial DNA: the result or consequence of enhanced generation of reactive oxygen species. Postepy Biochem 2010; 56: 139-146.
46. Padurariu M, Ciobica A, Dobrin I, Stefanescu C., Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010; 479: 317-320.
47. Réus GZ, Stringari RB, Souza B, et al., Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid Med Cell Longev 2010; 3: 325-331.
48. Valvassori SS, Petronilho FC, Réus GZ, et al., Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1064-1068. (Pubitemid 351609248)
49. Polydoro M, Schröder N, Lima MN, et al., Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 2004; 78: 751-756. (Pubitemid 39037735)
50. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J., Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 2004; 372: 157-160. (Pubitemid 39505248)
51. Lohr JB, Cadet JL, Lohr MA, et al., Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988; 14: 291-296.
52. Peet M, Laugharne J, Rangarajan N., Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993; 8: 151-153. (Pubitemid 23294920)
53. Andreassen OA, Ferrante RJ, Beal MF, Jorgensen HA., Oral dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience 1998; 87: 639-648. (Pubitemid 28396550)
54. Park SW, Lee CH, Lee JG, et al., Protective effects of atypical antipsychotic drugs against MPP+-induced oxidative stress in PC12 cells. Neurosci Res 2011; 69: 283-290.
55. Gaaecki P, Szemraj J, Bieakiewicz M, Florkowski A, Gaaecka E., Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009; 61: 436-447.
56. Kirkova M, Tzvetanova E, Vircheva S, Zamfirova R, Grygier B, Kubera M., Antioxidant activity of fluoxetine: studies in mice melanoma model. Cell Biochem Funct 2010; 28: 497-502.
57. Chung YC, Kim SR, Park JY, et al., Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011; 60: 963-974.
58. Streck EL, Amboni G, Scaini G, et al., Brain creatine kinase activity in an animal model of mania. Life Sci 2008; 82: 424-429.
59. Assis IC, Rezin GT, Comim CM, et al., Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev Bras Psiquiatr 2009; 31: 247-252.
60. Santos PM, Scaini G, Rezin GT, et al., Brain creatine kinase activity is increased by chronic administration of paroxetine. Brain Res Bull 2009; 80: 327-330.
61. Rezin GT, Gonçalves CL, Daufenbach JF, et al., Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress. Brain Res Bull 2009; 79: 418-421.
62. Hroudova J, Fisar Z., Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol Lett 2010; 31: 336-342.
63. Hirschfeld RM, Montgomery SA, Aguglia E., Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63: 826-837.
64. Fava M., New approaches to the treatment of refractory depression. J Clin Psychiatry 2000; 61: 26-32. (Pubitemid 30124147)
65. Morishita S., Clonazepam as a therapeutic adjunct to improve the management of depression: a brief review. Hum Psychopharmacol 2009; 24: 191-198.
66. Schatzberg AF., New approaches to managing psychotic depression. J Clin Psychiatry 2003; 64: 19-23. (Pubitemid 36206108)
67. Matthews JD, Bottonari KA, Polania LM., An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry 2002; 63: 1164-1170. (Pubitemid 36084062)